TY - JOUR
T1 - Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer
AU - Mukama, T.
AU - Fortner, R. T.
AU - Katzke, V.
AU - Hynes, L. C.
AU - Petrera, A.
AU - Hauck, S. M.
AU - Johnson, T.
AU - Schulze, M.
AU - Schiborn, C.
AU - Rostgaard-Hansen, A. L.
AU - Tjonneland, A.
AU - Overvad, K.
AU - Perez, M. J. S.
AU - Crous-Bou, M.
AU - -D., Chirlaque M.
AU - Amiano, P.
AU - Ardanaz, E.
AU - Watts, E. L.
AU - Travis, R. C.
AU - SACERDOTE, Carlotta
AU - Grioni, S.
AU - Masala, G.
AU - Signoriello, S.
AU - Tumino, R.
AU - Gram, I. T.
AU - Sandanger, T. M.
AU - Sartor, H.
AU - Lundin, E.
AU - Idahl, A.
AU - Heath, A. K.
AU - Dossus, L.
AU - Weiderpass, E.
AU - Kaaks, R.
PY - 2022
Y1 - 2022
N2 - Background: CA125 is the best available yet insufficiently sensitive biomarker for early detection of ovarian cancer. There is a need to identify novel biomarkers, which individually or in combination with CA125 can achieve adequate sensitivity and specificity for the detection of earlier-stage ovarian cancer. Methods: In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we measured serum levels of 92 preselected proteins for 91 women who had blood sampled ≤18 months prior to ovarian cancer diagnosis, and 182 matched controls. We evaluated the discriminatory performance of the proteins as potential early diagnostic biomarkers of ovarian cancer. Results: Nine of the 92 markers; CA125, HE4, FOLR1, KLK11, WISP1, MDK, CXCL13, MSLN and ADAM8 showed an area under the ROC curve (AUC) of ≥0.70 for discriminating between women diagnosed with ovarian cancer and women who remained cancer-free. All, except ADAM8, had shown at least equal discrimination in previous case-control comparisons. The discrimination of the biomarkers, however, was low for the lag-time of >9–18 months and paired combinations of CA125 with any of the 8 markers did not improve discrimination compared to CA125 alone. Conclusion: Using pre-diagnostic serum samples, this study identified markers with good discrimination for the lag-time of 0–9 months. However, the discrimination was low in blood samples collected more than 9 months prior to diagnosis, and none of the markers showed major improvement in discrimination when added to CA125.
AB - Background: CA125 is the best available yet insufficiently sensitive biomarker for early detection of ovarian cancer. There is a need to identify novel biomarkers, which individually or in combination with CA125 can achieve adequate sensitivity and specificity for the detection of earlier-stage ovarian cancer. Methods: In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we measured serum levels of 92 preselected proteins for 91 women who had blood sampled ≤18 months prior to ovarian cancer diagnosis, and 182 matched controls. We evaluated the discriminatory performance of the proteins as potential early diagnostic biomarkers of ovarian cancer. Results: Nine of the 92 markers; CA125, HE4, FOLR1, KLK11, WISP1, MDK, CXCL13, MSLN and ADAM8 showed an area under the ROC curve (AUC) of ≥0.70 for discriminating between women diagnosed with ovarian cancer and women who remained cancer-free. All, except ADAM8, had shown at least equal discrimination in previous case-control comparisons. The discrimination of the biomarkers, however, was low for the lag-time of >9–18 months and paired combinations of CA125 with any of the 8 markers did not improve discrimination compared to CA125 alone. Conclusion: Using pre-diagnostic serum samples, this study identified markers with good discrimination for the lag-time of 0–9 months. However, the discrimination was low in blood samples collected more than 9 months prior to diagnosis, and none of the markers showed major improvement in discrimination when added to CA125.
UR - https://iris.uniupo.it/handle/11579/199650
U2 - 10.1038/s41416-021-01697-z
DO - 10.1038/s41416-021-01697-z
M3 - Article
SN - 0007-0920
VL - 126
SP - 1301
EP - 1309
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 9
ER -
